Rephlmmune Biotechnology Inc.
Update：2024/07/15
Industries
Main Industry
Biotechnology
Main Product/Service
RephImmune is pioneering a new frontier in cancer immunotherapy with its proprietary platform, Reconstitute-Immunity Antigen-Cell Engager (RACE). This cutting-edge technology is rooted in regeneration biology and is specifically designed to reprogram and rebuild the immune system to effectively target and eliminate solid tumors.
At the core of RACE is a sophisticated algorithmic framework developed by RephImmune, which enables the identification, reassembly, and regeneration of immune components. The platform begins with the selection of 150 promising protein candidates and expands into a vast library of over 500,000 synthetically engineered novel proteins. These proteins are carefully designed and verified for their ability to modulate immune responses and engage tumor-specific antigens.
What sets RephImmune apart is its capacity to reconstitute cellular immunity across 13 different types of immune cells, including various subsets of T cells and innate immune cells. Through this process, the company has developed a novel engineered RACE-T cell specifically designed to attack and destroy solid tumors.
Importantly, the RACE platform is AI-compatible, meaning it can be trained and optimized through machine learning models. This integration of computational biology and artificial intelligence allows for continuous improvement and personalization of immunotherapy strategies, making RephImmune’s approach not only innovative but also scalable and adaptive to future clinical challenges.
At the core of RACE is a sophisticated algorithmic framework developed by RephImmune, which enables the identification, reassembly, and regeneration of immune components. The platform begins with the selection of 150 promising protein candidates and expands into a vast library of over 500,000 synthetically engineered novel proteins. These proteins are carefully designed and verified for their ability to modulate immune responses and engage tumor-specific antigens.
What sets RephImmune apart is its capacity to reconstitute cellular immunity across 13 different types of immune cells, including various subsets of T cells and innate immune cells. Through this process, the company has developed a novel engineered RACE-T cell specifically designed to attack and destroy solid tumors.
Importantly, the RACE platform is AI-compatible, meaning it can be trained and optimized through machine learning models. This integration of computational biology and artificial intelligence allows for continuous improvement and personalization of immunotherapy strategies, making RephImmune’s approach not only innovative but also scalable and adaptive to future clinical challenges.
Founded Year
2023
Unified Business No.
94106815
Status
Active
Number of Employees
0
Total Paid-in
Capital
18,702,173 (NT$)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Location of Company
Taiwan
, Taipei City
Exclusive content for members
Members-only content. Please log in to access.
Introduction
RephImmune is a preclinical-stage biotech company incubated in Boston and incorporated in Taiwan. We are dedicated to revolutionizing solid tumor cell therapy through our groundbreaking technology, RACE (Reconstitute-Immunity Antigen-Cell Engager): a unique engine in engineered cell therapy. Unlike conventional cell therapies, RACE bypasses traditional signaling pathways, unlocking the full potential of immune cells. With unparalleled advantages evident in pre-clinical data, RACE stands out in transformative advancements. Join us in accelerating RACE breakthroughs to have a clinical impact on more cancer patients!
